Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels

Urol Oncol. 2024 Dec;42(12):455.e9-455.e13. doi: 10.1016/j.urolonc.2024.07.013. Epub 2024 Sep 10.

Abstract

Purpose: MiR-371a-3p represents a novel liquid biomarker that detects all histologies of germ-cell tumors (GCT) except teratoma. However, it is currently unclear whether miR-371a-3p results obtained directly from RT-PCR (raw Cq) or normalized for housekeeper genes and transformed into the relative quantity (RQ) value should be used and at what cut-off level. The purpose of this research was to evaluate, which values should be used, and a potential cut-off level for relapse-detection to inform subsequent studies.

Materials and methods: We applied a CE-certified qRT-PCR test to measure miR-371a-3p at each follow-up visit during active surveillance in 34 men with stage I testicular GCT. MiR-371a-3p levels were calculated by the ΔΔ method.

Results: About 18 Patients had pure seminoma and 16 had mixed or nonseminomatous testicular GCT. Recurrences were detected in 10 patients and were correctly identified by both raw and housekeeper-normalized miR-371a-3p serum levels. The raw Cq, with a cut-off value of <28, resulted in only 1 false positive (3%), whereas RQ, with a cut-off value of >15, produced 6 false positive results (17%). Most of these false positive results normalized in subsequent measurements. The RQ approach detected recurrence in 1 patient 6 months earlier than the raw Cq approach.

Conclusion: Our preliminary data suggest that this CE-certified assay, using previously suggested cut-off values, is a promising method for detecting disease recurrence, provided a confirmatory second test is conducted to identify false positive results. To avoid unnecessary scans or overtreatment, we are currently validating this assay and cut-offs in a prospective cohort study.

Keywords: Active surveillance; Biomarker; Follow-up; MicroRNAs; Testicular neoplasms.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics
  • Cohort Studies
  • Humans
  • Male
  • MicroRNAs* / blood
  • Middle Aged
  • Neoplasm Recurrence, Local* / blood
  • Neoplasm Recurrence, Local* / diagnosis
  • Neoplasm Recurrence, Local* / genetics
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal* / blood
  • Neoplasms, Germ Cell and Embryonal* / diagnosis
  • Neoplasms, Germ Cell and Embryonal* / genetics
  • Prospective Studies
  • Testicular Neoplasms* / blood
  • Testicular Neoplasms* / diagnosis
  • Testicular Neoplasms* / genetics
  • Testicular Neoplasms* / pathology
  • Watchful Waiting
  • Young Adult

Substances

  • MIRN371 microRNA, human
  • MicroRNAs
  • Biomarkers, Tumor

Supplementary concepts

  • Testicular Germ Cell Tumor